Sutro Biopharma, Inc. (STRO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sutro Biopharma, Inc. (STRO) Healthcare & Pipeline Overview

Sutro Biopharma, Inc. is a clinical-stage biotechnology company specializing in antibody-drug conjugates (ADCs) and bispecific antibodies for cancer and autoimmune diseases, leveraging its proprietary XpressCF+ platform. With ongoing Phase 1 clinical trials and strategic collaborations, Sutro is positioned to address unmet needs in oncology and immunology.

What Is the Investment Thesis for STRO?

Sutro Biopharma presents a notable research candidate due to its innovative XpressCF+ platform and promising pipeline of antibody-drug conjugates (ADCs). The company's lead product candidates, STRO-001 and STRO-002, are currently in Phase 1 clinical trials, targeting significant unmet needs in multiple myeloma, non-Hodgkin lymphoma, ovarian, and endometrial cancers. Strategic collaborations with Merck and Celgene provide financial validation and potential for future revenue streams. The company's gross margin stands at 98.4%, reflecting the potential profitability of its platform. Key value drivers include successful clinical trial outcomes, expansion of the pipeline through internal development and partnerships, and potential for regulatory approvals and commercialization of its ADC candidates. However, the company's negative profit margin of -186.5% highlights the risks associated with clinical-stage biotechnology companies, including high R&D expenses and the uncertainty of drug development. Positive clinical data and strategic partnerships will be critical for driving long-term value.

Based on FMP financials and quantitative analysis

STRO Key Highlights

• Market capitalization of $228M reflects investor sentiment and growth potential in the biotechnology sector.
• Gross margin of 98.4% indicates efficient manufacturing processes and high potential profitability upon commercialization of products.
• Profit margin of -186.5% highlights the significant R&D investments typical of clinical-stage biotechnology companies.
• Beta of 1.31 suggests the stock is more volatile than the market, reflecting the high-risk, high-reward nature of biotechnology investments.
• Collaboration agreements with Merck and Celgene validate the company's technology and provide financial resources for pipeline development.

Who Are STRO's Competitors?

STRO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are STRO's Key Strengths?

• Proprietary XpressCF+ platform enables rapid and efficient development of protein therapeutics.
• Strong pipeline of ADC candidates in clinical development.
• Established collaborations with major pharmaceutical companies.
• Experienced management team with expertise in drug discovery and development.

What Are STRO's Weaknesses?

• Clinical-stage company with no approved products and limited revenue.
• High R&D expenses and negative profit margin.
• Reliance on successful clinical trial outcomes and regulatory approvals.
• Competition from other biotechnology and pharmaceutical companies.

What Could Drive STRO Stock Higher?

• Data readouts from Phase 1 clinical trials of STRO-001 in multiple myeloma and non-Hodgkin lymphoma.
• Data readouts from Phase 1 clinical trials of STRO-002 in ovarian and endometrial cancers.
• Expansion of the ADC pipeline through internal development and partnerships.
• Potential for new collaboration agreements with pharmaceutical companies.

What Are the Key Risks for STRO?

• Financial-distress signal — its Altman Z-Score of -5.82 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or regulatory setbacks for STRO-001 and STRO-002.
• Competition from other companies developing similar therapies.
• High R&D expenses and negative profit margin.
• Patent expirations and intellectual property challenges.

What Are the Growth Opportunities for STRO?

• Expansion of ADC Pipeline: Sutro Biopharma has the opportunity to expand its pipeline of antibody-drug conjugates (ADCs) beyond STRO-001 and STRO-002. The global ADC market is projected to reach $29.4 billion by 2028, growing at a CAGR of 22.7% from 2021 (Source: Global Market Insights). By leveraging its XpressCF+ platform, Sutro can develop novel ADCs targeting additional cancer indications and autoimmune disorders, addressing unmet medical needs and driving revenue growth. The timeline for this growth opportunity is ongoing, with continuous research and development efforts focused on identifying and validating new ADC targets.
• Strategic Partnerships and Licensing Agreements: Sutro Biopharma can further expand its reach and resources through strategic partnerships and licensing agreements with pharmaceutical companies. Collaborations with Merck and Celgene have already provided financial validation and access to expertise. By forging new partnerships, Sutro can accelerate the development and commercialization of its pipeline candidates, as well as gain access to new technologies and markets. The timeline for this growth opportunity is ongoing, with continuous efforts to identify and secure strategic alliances.
• Advancement of STRO-001 and STRO-002 through Clinical Trials: The successful advancement of STRO-001 and STRO-002 through clinical trials represents a significant growth opportunity for Sutro Biopharma. Positive clinical data demonstrating the safety and efficacy of these ADC candidates could lead to regulatory approvals and commercialization, generating substantial revenue streams. The timeline for this growth opportunity is dependent on the progress of ongoing Phase 1 trials and subsequent clinical development stages, with potential for regulatory submissions in the next 3-5 years.
• Expansion into New Therapeutic Areas: Sutro Biopharma has the potential to expand its focus beyond cancer and autoimmune disorders into new therapeutic areas. The XpressCF+ platform can be applied to the development of protein therapeutics for a wide range of diseases, including infectious diseases, metabolic disorders, and neurological conditions. By diversifying its pipeline, Sutro can reduce its reliance on specific therapeutic areas and capitalize on emerging market opportunities. The timeline for this growth opportunity is long-term, with initial research and development efforts focused on identifying and validating new therapeutic targets.
• Manufacturing Capabilities and Technology Licensing: Sutro Biopharma's XpressCF+ platform provides a competitive advantage in the development and manufacturing of protein therapeutics. The company can leverage its manufacturing capabilities to produce its own pipeline candidates, as well as offer contract manufacturing services to other biotechnology and pharmaceutical companies. Additionally, Sutro can license its XpressCF+ platform to other organizations, generating revenue streams and expanding its reach within the industry. The timeline for this growth opportunity is ongoing, with continuous efforts to optimize manufacturing processes and expand technology licensing agreements.

What Opportunities Does STRO Have?

• Expansion of ADC pipeline into new therapeutic areas.
• Strategic partnerships and licensing agreements to accelerate development and commercialization.
• Advancement of STRO-001 and STRO-002 through clinical trials.
• Potential for regulatory approvals and commercialization of ADC candidates.

What Threats Does STRO Face?

• Clinical trial failures and regulatory setbacks.
• Competition from other companies developing similar therapies.
• Patent expirations and intellectual property challenges.
• Changes in healthcare regulations and reimbursement policies.

What Are STRO's Competitive Advantages?

• Proprietary XpressCF+ platform for efficient protein synthesis and conjugation.
• Strong intellectual property portfolio protecting its technology and product candidates.
• Established collaborations with major pharmaceutical companies.
• Clinical-stage pipeline with promising ADC candidates.

What Does STRO Do?

Sutro Biopharma, Inc., founded in 2003 and headquartered in South San Francisco, California, is a clinical-stage drug discovery, development, and manufacturing company. Originally named Fundamental Applied Biology, Inc., the company rebranded to reflect its focus on innovative protein therapeutics. Sutro Biopharma specializes in creating novel treatments for cancer and autoimmune disorders, utilizing its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+. This platform enables the rapid and efficient development of antibody-drug conjugates (ADCs) and bispecific antibodies. The company's lead product candidates include STRO-001, an ADC targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, an ADC targeting folate receptor-alpha for patients with ovarian and endometrial cancers. Both STRO-001 and STRO-002 are currently in Phase 1 clinical trials, evaluating their safety and efficacy. Sutro Biopharma has established collaboration and license agreements with major pharmaceutical companies, including Merck to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders, and Celgene Corporation (now part of Bristol Myers Squibb) to discover and develop bispecific antibodies and/or ADCs focused on immuno-oncology. These partnerships provide Sutro with financial resources and expertise to advance its pipeline of novel therapeutics. Sutro's focus on innovative protein therapeutics and strategic collaborations positions it as a key player in the biotechnology industry.

What Products and Services Does STRO Offer?

• Develops antibody-drug conjugates (ADCs) for cancer and autoimmune disorders.
• Utilizes its proprietary XpressCF+ platform for cell-free protein synthesis and site-specific conjugation.
• Conducts Phase 1 clinical trials for its lead product candidates, STRO-001 and STRO-002.
• Collaborates with pharmaceutical companies like Merck and Celgene for research and development.
• Focuses on creating novel protein therapeutics for unmet medical needs.
• Manufactures protein therapeutics using its integrated platform.

How Does STRO Make Money?

• Develops and out-licenses novel protein therapeutics.
• Generates revenue through collaboration agreements and licensing fees.
• Advances its own pipeline of ADC candidates through clinical trials.
• Potentially generates revenue through commercialization of approved products.

What Industry Does STRO Operate In?

Sutro Biopharma operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The market for antibody-drug conjugates (ADCs) is experiencing significant growth, driven by the increasing prevalence of cancer and autoimmune disorders, as well as advancements in targeted therapies. Sutro's XpressCF+ platform positions it to capitalize on this trend by enabling the efficient development of novel ADCs. The company competes with other biotechnology firms, pharmaceutical companies, and research institutions in the development of innovative protein therapeutics. Success in this industry requires strong scientific expertise, robust clinical trial data, and strategic partnerships to navigate the complex regulatory and commercial landscape.

Who Are STRO's Key Customers?

• Patients with cancer and autoimmune disorders.
• Pharmaceutical companies through collaboration and licensing agreements.
• Healthcare providers who prescribe and administer Sutro's therapies.
• Research institutions involved in clinical trials and development.

FY2026 estForward Outlook

Wall Street analysts project Sutro Biopharma, Inc. revenue of about $44.6M for fiscal 2026, with EPS near $-8.53. The estimate reflects 9 contributing analysts.

F-Score 3/9Financial Health

Sutro Biopharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.82 places it in the distress zone, a signal of elevated financial risk.

ROE 193%Key Financial Metrics

Return on equity for Sutro Biopharma, Inc. stands at 192.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -63.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -67.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.12 indicates the company holds enough short-term assets to cover its near-term obligations.

Sutro Biopharma, Inc. (STRO) Valuation Context

Valued at $228M, STRO is classified as a micro-cap stock. Relative to its peer group, STRO's quantitative score of 14/100 is below the peer average of 70/100.

Company Profile

Sutro Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Jane Chung. STRO has traded publicly since 2018.

STRO Financials

STRO Latest News

No recent news available for STRO.

STRO Analyst Consensus

STRO MoonshotScore

Common Questions About STRO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources